We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-11.4%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$57.4B
AUM Growth
-$7.29B
Cap. Flow
+$861M
Cap. Flow %
1.5%
Top 10 Hldgs %
21.3%
Holding
3,843
New
205
Increased
1,398
Reduced
1,819
Closed
309

Sector Composition

Rank Sector Weight
1 Technology 9.78%
2 Financials 8.85%
3 Healthcare 8.68%
4 Industrials 6.29%
5 Consumer Discretionary 5.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ABBV icon
3301
CALL
AbbVie
ABBV
$438B
$87K ﹤0.01%
69,800
-41,200
-37% -$3.62M
CCI icon
3302
CALL
Crown Castle
CCI
$31.3B
$87K ﹤0.01%
+32,900
New +$3.61M
HBM icon
3303
Hudbay
HBM
$12.4B
$87K ﹤0.01%
18,339
+1,575
+9% +$7.41K
BLCM
3304
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$86K ﹤0.01%
2,951
+521
+21% +$23.1K
AGRO icon
3305
Adecoagro
AGRO
$1.39B
$83K ﹤0.01%
11,896
-13,797
-54% -$101K
DMF
3306
DELISTED
BNY Mellon Municipal Income
DMF
$83K ﹤0.01%
10,949
-15,489
-59% -$118K
NIO icon
3307
NIO
NIO
$12.1B
$83K ﹤0.01%
+12,992
New +$90.4K
PLUR icon
3308
Pluri
PLUR
$19.9M
$83K ﹤0.01%
1,316
DUC
3309
DELISTED
Duff & Phelps Utility & Corporate Bond Trust
DUC
$83K ﹤0.01%
+10,052
New +$82.3K
CMRE icon
3310
Costamare
CMRE
$1.74B
$82K ﹤0.01%
18,696
+430
+2% +$2.27K
BEST
3311
DELISTED
BEST Inc. American Depositary Shares, each representing twenty (20) Class A Ordinary Shares
BEST
$82K ﹤0.01%
996
+72
+8% +$7.48K
JEMD
3312
DELISTED
Nuveen Emerging Markets Debt 2022 Target Term Fund, Common Shares of Beneficial Interest, $0.01 par value per share
JEMD
$82K ﹤0.01%
+10,750
New +$83.2K
SMRT
3313
DELISTED
Stein Mart Inc
SMRT
$82K ﹤0.01%
76,502
-5,010
-6% -$8.61K
EPM icon
3314
Evolution Petroleum
EPM
$134M
$81K ﹤0.01%
11,824
-59,833
-83% -$561K
BKCC
3315
DELISTED
BlackRock Capital Investment Corporation
BKCC
$81K ﹤0.01%
+15,345
New +$88.4K
MN
3316
DELISTED
MANNING & NAPIER, INC.
MN
$81K ﹤0.01%
45,983
-2,917
-6% -$6.04K
PBT
3317
Permian Basin Royalty Trust
PBT
$1.52B
$80K ﹤0.01%
13,477
-4,884
-27% -$34.4K
SRF
3318
DELISTED
THE CUSHING ROYALTY & INCOME FUND
SRF
$80K ﹤0.01%
12,438
-5,189
-29% -$41.1K
ACTG icon
3319
Acacia Research
ACTG
$465M
$79K ﹤0.01%
26,640
+3,000
+13% +$9.28K
CLNE icon
3320
Clean Energy Fuels
CLNE
$355M
$79K ﹤0.01%
46,100
-1,200
-3% -$2.66K
EMITF
3321
DELISTED
Elbit Imaging Ltd
EMITF
$79K ﹤0.01%
+60,800
New +$113K
UUU icon
3322
Universal Safety Products Inc
UUU
$10.9M
$78K ﹤0.01%
73,513
GRF
3323
Eagle Capital Growth Fund
GRF
$41.8M
$77K ﹤0.01%
+10,571
New +$78.6K
RMTI icon
3324
Rockwell Medical
RMTI
$27M
$76K ﹤0.01%
304
-942
-76% -$375K
AKS
3325
DELISTED
AK Steel Holding Corp
AKS
$76K ﹤0.01%
33,859
-18,545
-35% -$67K

Similar funds

Raymond James & Associates's Q4 2018 Portfolio in Review

As of Q4 2018, Raymond James & Associates held 3,843 positions worth $57.4B, down 11% from $64.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Raymond James & Associates's Q4 2018 filing shows 205 new, 1,398 increased, 1,819 reduced and 309 closed positions. Its largest new stake was Linde: 549,404 shares worth $87.1M. The largest sale was Oracle, an estimated $124M.

By sector, the portfolio is most concentrated in Technology at 9.8% of assets, down from 11% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q4 2018 buy was Linde: 549,404 shares worth $87.1M.
  • Raymond James & Associates added most to State Street SPDR S&P 500 ETF Trust in Q4 2018, an estimated $368M increase.
  • Raymond James & Associates's biggest Q4 2018 reduction was Oracle, cutting an estimated $124M.
  • Raymond James & Associates fully exited Praxair Inc in Q4 2018, selling an estimated $110M.
  • Raymond James & Associates's ten largest holdings make up 21% of its $57.4B portfolio in Q4 2018.
  • Raymond James & Associates opened 205 new positions and closed 309 in Q4 2018.
  • Raymond James & Associates's portfolio value fell 11% quarter-over-quarter to $57.4B.

Based on Raymond James & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.